Cannabidiol As an Intervention for Addictive Behaviors: A Systematic Review of the Evidence

Overview

Journal Subst Abuse

Publisher Sage Publications

Specialty Psychiatry

Date 2015 Jun 10

PMID 26056464

Citations 61

Authors

Melissa Prudhomme

Romulus Cata

Didier Jutras-Aswad

Affiliations

Soon will be listed here.

Abstract

Drug addiction is a chronically relapsing disorder characterized by the compulsive desire to use drugs and a loss of control over consumption. Cannabidiol (CBD), the second most abundant component of cannabis, is thought to modulate various neuronal circuits involved in drug addiction. The goal of this systematic review is to summarize the available preclinical and clinical data on the impact of CBD on addictive behaviors. MEDLINE and PubMed were searched for English and French language articles published before 2015. In all, 14 studies were found, 9 of which were conducted on animals and the remaining 5 on humans. A limited number of preclinical studies suggest that CBD may have therapeutic properties on opioid, cocaine, and psychostimulant addiction, and some preliminary data suggest that it may be beneficial in cannabis and tobacco addiction in humans. Further studies are clearly necessary to fully evaluate the potential of CBD as an intervention for addictive disorders.

Citing Articles

Cannabidiol Supplements in Romania: Bridging the Gap Between Marketed Claims and Clinical Reality.

Andrei C, Nitulescu G, Nitulescu G, Zanfirescu A Pharmacy (Basel). 2024; 12(6).

PMID: 39728841 PMC: 11676264. DOI: 10.3390/pharmacy12060176.

Cannabidiol, a plant-derived compound, is an emerging strategy for treating cognitive impairments: comprehensive review of randomized trials.

Arias A, Vadell K, Vashist A, Kolishetti N, Lakshmana M, Nair M Front Pharmacol. 2024; 15:1403147.

PMID: 39323633 PMC: 11422111. DOI: 10.3389/fphar.2024.1403147.

Cannabidiol Protects against the Reinstatement of Oxycodone-Induced Conditioned Place Preference in Adolescent Male but Not Female Rats: The Role of MOR and CB1R.

Socha J, Grochecki P, Marszalek-Grabska M, Skrok A, Smaga I, Slowik T Int J Mol Sci. 2024; 25(12).

PMID: 38928357 PMC: 11204276. DOI: 10.3390/ijms25126651.

The acute effects of cannabis, with and without cannabidiol, on attentional bias to cannabis related cues: a randomised, double-blind, placebo-controlled, cross-over study.

Hall D, Lawn W, Ofori S, Trinci K, Borissova A, Mokrysz C Psychopharmacology (Berl). 2024; 241(6):1125-1134.

PMID: 38416223 PMC: 11106134. DOI: 10.1007/s00213-024-06543-7.

Orphan peptide and G protein-coupled receptor signalling in alcohol use disorder.

Anversa R, Maddern X, Lawrence A, Walker L Br J Pharmacol. 2023; 181(5):595-609.

PMID: 38073127 PMC: 10953447. DOI: 10.1111/bph.16301.

References

Fusar-Poli P, Crippa J, Bhattacharyya S, Borgwardt S, Allen P, Martin-Santos R . Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009; 66(1):95-105. DOI: 10.1001/archgenpsychiatry.2008.519. View

Reid M, Bornheim L . Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochem Pharmacol. 2001; 61(11):1357-67. DOI: 10.1016/s0006-2952(01)00616-5. View

Morgan C, Das R, Joye A, Curran H, Kamboj S . Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013; 38(9):2433-6. DOI: 10.1016/j.addbeh.2013.03.011. View

Bhargava H . Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice. Psychopharmacology (Berl). 1976; 49(3):267-70. DOI: 10.1007/BF00426828. View

Zanelati T, Biojone C, Moreira F, Guimaraes F, Joca S . Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol. 2009; 159(1):122-8. PMC: 2823358. DOI: 10.1111/j.1476-5381.2009.00521.x. View

Leweke F, Piomelli D, Pahlisch F, Muhl D, Gerth C, Hoyer C . Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012; 2:e94. PMC: 3316151. DOI: 10.1038/tp.2012.15. View

Hampson A, Grimaldi M, Axelrod J, Wink D . Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998; 95(14):8268-73. PMC: 20965. DOI: 10.1073/pnas.95.14.8268. View

Zuardi A, Morais S, Guimaraes F, Mechoulam R . Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995; 56(10):485-6. View

Hine B, Torrelio M, Gershon S . Interactions between cannabidiol and delta9-THC during abstinence in morphine-dependent rats. Life Sci. 1975; 17(6):851-7. DOI: 10.1016/0024-3205(75)90435-x. View

10.

Crippa J, Hallak J, Machado-de-Sousa J, Queiroz R, Bergamaschi M, Chagas M . Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther. 2012; 38(2):162-4. DOI: 10.1111/jcpt.12018. View

11.

Thomas A, Baillie G, Phillips A, Razdan R, Ross R, Pertwee R . Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007; 150(5):613-23. PMC: 2189767. DOI: 10.1038/sj.bjp.0707133. View

12.

Consroe P, Carlini E, Zwicker A, Lacerda L . Interaction of cannabidiol and alcohol in humans. Psychopharmacology (Berl). 1979; 66(1):45-50. DOI: 10.1007/BF00431988. View

13.

Hamelink C, Hampson A, Wink D, Eiden L, Eskay R . Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J Pharmacol Exp Ther. 2005; 314(2):780-8. PMC: 4183207. DOI: 10.1124/jpet.105.085779. View

14.

DSouza D, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T . Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. 2008; 33(10):2505-16. PMC: 3799954. DOI: 10.1038/sj.npp.1301643. View

15.

Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee R, Robson P . Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006; 15(5):349-53. DOI: 10.1097/01.ijg.0000212260.04488.60. View

16.

Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G . Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend. 2010; 114(2-3):242-5. DOI: 10.1016/j.drugalcdep.2010.09.020. View

17.

Hine B, Torrelio M, Gershon S . Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats. Res Commun Chem Pathol Pharmacol. 1975; 12(1):185-8. View

18.

Cunha J, Carlini E, Pereira A, Ramos O, Pimentel C, Gagliardi R . Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980; 21(3):175-85. DOI: 10.1159/000137430. View

19.

Morgan C, Freeman T, Schafer G, Curran H . Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010; 35(9):1879-85. PMC: 2906701. DOI: 10.1038/npp.2010.58. View

20.

Russo E, Burnett A, Hall B, Parker K . Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005; 30(8):1037-43. DOI: 10.1007/s11064-005-6978-1. View